You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Transforming the lives of people affected by urologic conditions, including overactive bladder & bladder cancer.
With over 30 years of experience in urology, we have a profound understanding of the daily challenges faced by patients. These challenges inspire our commitment to making a meaningful difference in their lives.
Overactive bladder (OAB)
OAB is characterized by urgency, urinary incontinence, frequency, and nocturia,1,2 significantly impacting the quality of life for both men and women. Among these symptoms, urgency is often the most bothersome.3
At Astellas, our vision is to create a future where the stigma and embarrassment often associated with OAB are eliminated. We strive for a world where this condition is not merely managed but overcome, empowering individuals to connect with life fully.
Urothelial carcinoma (UC)
UC, also known as transitional cell carcinoma (TCC) is the most common type of bladder cancer, accounting for approximately 90% of all cases.8,9 It begins in the urothelial cells that line the inside of the bladder and other parts of the urinary tract.10
At Astellas, we believe that collaboration is essential for driving meaningful change in healthcare. By partnering with research institutions, healthcare providers, patient organizations, and other stakeholders, we ensure that our therapies and initiatives are closely aligned with the needs of those we serve.
1Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth international consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40.
2Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–8.
3Wagg A, Ackerman A. Lenore Ackerman, Lai H. Henry, Newman Diane K. Review of the Impact and Burden of Urinary Urgency on Adults with Overactive Bladder, International Journal of Clinical Practice. Volume 2024.
4Irwin D. E., Kopp Z. S., Agatep B., Milsom I., and Abrams P., Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction, BJU International. (2011) 108, no. 7, 1132–1138.
5Stewart W. F., Van Rooyen J. B., Cundiff G. W., Abrams P., Herzog A. R., Corey R., Hunt T. L., and Wein A. J., Prevalence and burden of overactive bladder in the United States, World Journal of Urology. (2003) 20, no. 6, 327–336.
6Brodsky CN, Sitto HM, Wittmann D, Wallner LP, Streur C, DeJonckheere M, et al. "There is a lot of shame that comes with this": A qualitative study of patient experiences of isolation, embarrassment, and stigma associated with overactive bladder. Neurourol Urodyn. 2024 Nov;43(8):1817-1825.
7Milsom, Ian et al. Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic Review. European Urology, Volume 65, Issue 1, 79 – 95.
8Wong MC, Fung FD, Leung C, et al. Scientific Reports. 2018;8(1):1129.
9American Cancer Society. What is Bladder Cancer? Available at: https://www.cancer.org/cancer/types/bladder-cancer/about/what-is-bladder-cancer.html#. Last accessed January 2024.
10Cancer.Net (ASCO). Bladder Cancer: Introduction. Available at: https://www.cancer.net/cancer-types/bladder-cancer/view-all. Last accessed January 2024.
11GLOBOCAN IARC 2020: Worldwide 5-year Cancer Prevalence. Available at: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=2&statistic=5&prevalence=1&population_ group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1#collapse-group-0-4. Last accessed January 2024.
12WCRF/AICR. (2019). Bladder cancer statistics. Available at: https://www.wcrf.org/cancer-trends/bladder-cancer-statistics/. Last accessed January 2024.
13EU Science Hub. Epidemiology of bladder cancer in Europe. Available at: https://publications.jrc.ec.europa.eu/repository/handle/JRC101380. Last accessed January 2024.
14WBCPC. 2020. Bladder Cancer Facts. Available at: https://worldbladdercancer.org/wp-content/uploads/2020/09/Bladder-Cancer-WBCPC-Infographic.pdf. Last accessed January 2024.
15World Bladder Cancer Patient Coalition. GLOBOCAN 2020: Bladder cancer 10th most commonly diagnosed worldwide. Available at: https://worldbladdercancer.org/news_events/globocan-2020-bladder-cancer-10th-most-commonly-diagnosedworldwide/. Last accessed: January 2024
16World Federation of Incontinence and Pelvic Problems https://wfipp.org/commitment-to-collaboration-in-continence-care-4cs-executive-summary/#:~:text=The%20Commitment%20to%20Collaboration%20in,aligned%20with%20the%204Cs%20objectives. Last accessed November 2024.
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?